Grants per year
Personal profile
Research Interests
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Clinical trials
Training Experience
| 1995 | Internship, Mount Sinai Hospital, New York |
| 1996 | Residency, Mount Sinai Hospital, New York |
Expertise related to UN Sustainable Devlopment Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, MD, University of Rome La Sapienza
… → 1988
Research interests
- Blood Cancer (leukemia and lymphomas)
- Clinical Research
Fingerprint
Dive into the research topics where Barbara Pro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #DS3201-A-J101: A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects with Lymphomas
4/7/21 → 4/7/24
Project: Research project
-
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
Pearse, W. B., Petrich, A. M., Gordon, L. I., Karmali, R., Winter, J. N., Ma, S., Kaplan, J. B., Behdad, A., Klein, A., Jovanovic, B., Helenowski, I., Smith, S. M., Evens, A. M. & Pro, B., 2021, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Article › peer-review
-
Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides
Walker, C. J., Espinosa, M. L., Mehta-Shah, N., Pro, B., Guitart, J. & Kuzel, T. M., Mar 1 2021, In: Journal of drugs in dermatology : JDD. 20, 3, p. 349-350 2 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma
Samaniego, F., McLaughlin, P., Neelapu, S. S., Feng, L., Fanale, M., Nastoupil, L., Rodriguez, M. A., Pro, B., Taylor, E., Hagemeister, F. B. & Fowler, N., 2021, In: Leukemia and Lymphoma. 62, 1, p. 58-67 10 p.Research output: Contribution to journal › Article › peer-review
-
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin
Nizamuddin, I., Galvez, C. & Pro, B., Apr 2021, In: Seminars in Hematology. 58, 2, p. 85-94 10 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides
Walker, C. J., Donnelly, E. D., Moreira, J., Mehta, J., Mittal, B. B., Choi, J., Zhou, X. A., Guitart, J. & Pro, B., Jan 2021, In: JAAD Case Reports. 7, p. 87-90 4 p.Research output: Contribution to journal › Article › peer-review
Open Access